Zobrazeno 1 - 10 of 50 pro vyhledávání: '"Samantha, Budd Haeberlein"'
3
Amyloid-Related Imaging Abnormalities in 2 Phase 3 Studies Evaluating Aducanumab in Patients with Early Alzheimer Disease
Autor: Guanfang Wang, Samantha Budd Haeberlein, Spyros Chalkias, Kimberly Umans, Karen Smirnakis, Frederik Barkhof, Derk D. Purcell, Patrick Burkett, Joyce Suhy, Jerome Barakos, Stephen Salloway, Priya Singhal, Fiona Forrestal, Ying Tian
Publikováno v: JAMA Neurology, 79(1), 13-21. American Medical Association
Salloway, S, Chalkias, S, Barkhof, F, Burkett, P, Barakos, J, Purcell, D, Suhy, J, Forrestal, F, Tian, Y, Umans, K, Wang, G, Singhal, P, Budd Haeberlein, S & Smirnakis, K 2022, ' Amyloid-Related Imaging Abnormalities in 2 Phase 3 Studies Evaluating Aducanumab in Patients with Early Alzheimer Disease ', JAMA Neurology, vol. 79, no. 1, pp. 13-21 . https://doi.org/10.1001/jamaneurol.2021.4161
JAMA Neurology
Key Points Question What are the characteristics of amyloid-related imaging abnormalities (ARIA) during aducanumab treatment in individuals with early Alzheimer disease? Findings In an integrated safety data set of 2 phase 3 clinical trials (EMERGE a
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::91e6460af171fc31f9c91d3f80934ed4
https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=85119965458&origin=inward
Zobrazit plný text záznamu
8
Trial of Cinpanemab in Early Parkinson's Disease
Autor: Anthony E, Lang, Andrew D, Siderowf, Eric A, Macklin, Werner, Poewe, David J, Brooks, Hubert H, Fernandez, Olivier, Rascol, Nir, Giladi, Fabrizio, Stocchi, Caroline M, Tanner, Ronald B, Postuma, David K, Simon, Eduardo, Tolosa, Brit, Mollenhauer, Jesse M, Cedarbaum, Kyle, Fraser, James, Xiao, Karleyton C, Evans, Danielle L, Graham, Inbal, Sapir, Jennifer, Inra, R Matthew, Hutchison, Minhua, Yang, Tara, Fox, Samantha, Budd Haeberlein, Tien, Dam, Laurice, Yang
Publikováno v: Lang, A E, Siderowf, A D, Macklin, E A, Poewe, W, Brooks, D J, Fernandez, H H, Rascol, O, Giladi, N, Stocchi, F, Tanner, C M, Postuma, R B, Simon, D K, Tolosa, E, Mollenhauer, B, Cedarbaum, J M, Fraser, K, Xiao, J, Evans, K C, Graham, D L, Sapir, I, Inra, J, Hutchison, R M, Yang, M, Fox, T, Budd Haeberlein, S, Dam, T & SPARK Investigators 2022, ' Trial of Cinpanemab in Early Parkinson's Disease ', The New England Journal of Medicine, vol. 387, no. 5, pp. 408-420 . https://doi.org/10.1056/NEJMoa2203395
BACKGROUND: Aggregated α-synuclein plays an important role in Parkinson's disease pathogenesis. Cinpanemab, a human-derived monoclonal antibody that binds to α-synuclein, is being evaluated as a disease-modifying treatment for Parkinson's disease.
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9b50a6abc4d9ecccdef2d7c021fbbee6
https://pubmed.ncbi.nlm.nih.gov/35921450
Zobrazit plný text záznamu
9
Alzheimer disease neuropathology in a patient previously treated with aducanumab
Autor: Edward D. Plowey, Thierry Bussiere, Raj Rajagovindan, Jennifer Sebalusky, Stefan Hamann, Christian von Hehn, Carmen Castrillo-Viguera, Alfred Sandrock, Samantha Budd Haeberlein, Christopher H. van Dyck, Anita Huttner
Publikováno v: Acta neuropathologica. 144(1)
Amyloid beta (Aβ) plaque is a defining pathologic feature of Alzheimer disease (AD). Aducanumab, a monoclonal IgG1 that selectively binds aggregated species of Aβ, has been shown by amyloid positron emission tomography (Amyloid PET) to reduce Aβ p
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::dc1b5f2313ceec8788b74f6643c2ba7d
https://pubmed.ncbi.nlm.nih.gov/35581440
Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání

Omezení vyhledávání
Plný text Recenzováno Digitální knihovna AV ČR
Zdroje